Ocuphire sees more success for Nyxol

 Ocuphire is on a winning streak. The ophthalmology company today reported positive results in the phase 2 Vega-1 trial for its lead product Nyxol in presbyopia. In the 150 patient study 61% of patients treated with Nyxol in combination with low-dose pilocarpine (LDP) showed a 15 letter improvement in their near vision after one hour compared with 28% of those in the placebo group. Presbyopia is the gradual age-related loss of the eyes’ ability to focus on nearby objects and is usually corrected with reading glasses or contact lenses. Ocuphire is hoping to offer the first pharmacological approach to the problem. However, the key question is whether the current six hour duration of treatment Nyxol provides will be enough to overcome the relative inconvenience of wearing glasses. This is the second piece of good news for Ocuphire, following a previous win in the phase 3 Mira-2 trial. In that study Nyxol hit its primary end point in correcting pharmacologically induced mydriasis – the medical dilation of pupils during eye exams. This second win sent shares in Ocuphire, which reversed into Rexahn Pharmaceuticals late last year, up 20%. A third phase 3 is due to report at the end of Q3, trialling Nyxol in night vision disturbances.

https://www.evaluate.com/vantage/articles/news/snippets/ocuphire-sees-more-success-nyxol